Japan’s MHLW Approves Pfizer and OPKO’s NGENLA® (Somatrogon), a New Long-Acting Treatment for Pediatric Growth Hormone Deficiency
January 20, 2022 08:00 ET
|
OPKO Health, Inc.; Pfizer Japan Inc.
TOKYO and MIAMI, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Pfizer Japan Inc. and OPKO Health, Inc. (NASDAQ: OPK) announced today that the next generation long-acting growth hormone injection, NGENLA®...
OPKO Health Announces Topline Results from Phase 2 Trial Evaluating RAYALDEE to Treat Symptomatic COVID-19 Outpatients
December 23, 2021 08:00 ET
|
OPKO Health, Inc.
MIAMI, Dec. 23, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) announces preliminary topline results from its Phase 2 trial with RAYALDEE® to treat mild-to-moderate COVID-19. This study...
OPKO Health Receives U.S. FDA Approval for the 4Kscore® Test
December 08, 2021 08:00 ET
|
OPKO Health, Inc.
MIAMI, Dec. 08, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that the U.S. Food and Drug Administration (FDA) has approved OPKO’s 4Kscore Test. This test is approved for...
OPKO Health Announces the Passing of Director Dr. Richard Lerner
December 06, 2021 08:00 ET
|
OPKO Health, Inc.
MIAMI, Dec. 06, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) announces that Director Richard A. Lerner, M.D. passed away on December 2nd at the age of 83. Dr. Lerner had served as a...
OPKO Health Announces Participation in Piper Sandler 33rd Annual Virtual Healthcare Conference
November 29, 2021 08:00 ET
|
OPKO Health, Inc.
MIAMI, Nov. 29, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that management will be participating in the Piper Sandler 33rd Annual Virtual Healthcare Conference taking...
OPKO Health Reports 2021 Third Quarter Business Highlights and Financial Results
October 28, 2021 16:15 ET
|
OPKO Health, Inc.
MIAMI, Oct. 28, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended September 30, 2021. Business Highlights ...
OPKO Health to Report Third Quarter 2021 Financial Results on October 28, 2021
October 25, 2021 10:57 ET
|
OPKO Health, Inc.
MIAMI, Oct. 25, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended September 30, 2021, as well as discuss financial...
Pfizer and OPKO Announce Extension of U.S. FDA Review of Biologics License Application of Somatrogon for Pediatric Growth Hormone Deficiency
September 24, 2021 16:24 ET
|
OPKO Health, Inc.
NEW YORK and MIAMI, Sept. 24, 2021 (GLOBE NEWSWIRE) -- Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the U.S. Food and Drug Administration (FDA) has extended the...
LeaderMed Group and OPKO Health Form Joint Venture to Develop and Commercialize Oxyntomodulin and Factor VIIa-CTP in China and Other Asian Territories
September 14, 2021 08:00 ET
|
OPKO Health, Inc.; LeaderMed Group
SHANGHAI and MIAMI, Sept. 14, 2021 (GLOBE NEWSWIRE) -- LeaderMed Health Group Limited, a pharmaceutical development company with operations based in Asia, and OPKO Health, Inc. (NASDAQ: OPK), a...
OPKO Health Completes Enrollment in Phase 2 Trial Evaluating RAYALDEE as a Treatment for Symptomatic COVID-19 Outpatients
August 30, 2021 16:17 ET
|
OPKO Health, Inc.
MIAMI, Aug. 30, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) announces the completion of enrollment in its Phase 2 trial with RAYALDEE® as a treatment for mild-to-moderate COVID-19. The...